PhRMA v. HHS
Executive Summary
D.C. federal court will hear additional arguments on the Pharmaceutical Research & Manufacturers of America's challenge of HHS' approval of the Michigan Medicaid supplemental rebate program Jan. 24. The court wants information on the effect the non-Medicaid aspects of the program will have on Medicaid beneficiaries. During oral arguments Jan. 6, the Department of Justice said the court should defer to HHS' approval (1"The Pink Sheet" Sept. 2, p. 6)...
You may also be interested in...
Michigan Rx Rebate Program Decision Should Be Left To HHS, DoJ Tells Court
HHS' approval of the Michigan Medicaid supplemental rebate program should be given deference in the Washington, D.C. federal court's review of the program, the Department of Justice said during oral arguments Aug. 28
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.